Slide 1: For personal use only
For personal use only “Never has scale been more important for the success and growth of a global business!”
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: About Us: The Measure of Life
For personal use only ABOUT US THE MEASURE OF LIFE Uscom are the experts in circulation delivering innovative, practice changing non-invasive cardiovascular and pulmonary monitoring devices. Our devices are patent protected advancements on current devices, and provide improved measurements of the vi
Slide 4: Overview: Our Vision and Drive
OVERVIEW For personal use only OUR VISION Uscom is an innovator in cardiovascular and pulmonary medical devices, developing new non-invasive technologies to address the challenges of global disease and health care. OUR DRIVE Uscom is driven by a commercial ambition to become a leader in the global h
Slide 5: Summary: Results, Achievements, Future
SUMMARY For personal use only RESULTS Record revenue, sales, cash receipts (up 307% 5yrs, 72% 2yrs, and 32% 5yr CAGR) $3.5M revenue with intermittent monthly/quarterly cash flow positivity 2 international acquisitions High value IP across 3 sectors High margin products ACHIEVEMENTS Leader in CV and
Slide 6: Uscom Today
USCOM For personal use only TODAY Reuters/Bloomberg UCM.AX/UCM.AU Market Cap $18M Current price $0.15 2017 VWAP $0.25 Shares on issue 114M Free float 100% Top 20 shareholders 65% Major Shareholders % Prof Rob Phillips 19.96 Mr Gary Davey 5.48 Dr Stephen Woodford 8.96
Slide 7: Overview: Products
OVERVIEW For personal use only PRODUCTS USCOM 1A – Ultrasonic Cardiac Output Monitor for sepsis, fluid, heart failure, hypertension, pre-eclampsia BP+ - Blood pressure and heart failure for hypertension, pharma, heart failure SpiroSonic – Ultrasonic spirometers for asthma and COPD GLOBAL SALES Curre
Slide 8: Governance
GOVERNANCE For personal use only Ms Sheena Jack Associate Prof Rob Phillips Mr Christian Bernecker Mr Brett Crowley Non-executive Executive Non-executive Secretary CEO of HCF Uscom Limited Mr Chao Xian (David) He Non-executive
Slide 9: Medical Advisory
MEDICAL ADVISORY For personal use only Prof. Colin Sullivan Australia Sleep Medicine Prof. C.P.Lau | Hong Kong Cardiolology/Electrophysiology Prof. Didier Payen | France Critical Care Medicine Prof. Peter Lichtenthal | USA Cardiac Anaesthesia Prof. Nigel Sharrock | USA Anaesthesia Prof. Stephane Car
Slide 10: Our Results: Total Annual Revenue
O U R R E S U LT S For personal use only $3,498,959.00 $2,936,504.00 T O TA L A N N U A L R E V E N U E $2,039,426.00 Strong revenue, sales and receipts growth 307% growth over the last 5 years 72% in the last 2 years $1,377,716.00 CAGR of 30-40% PA for the last 5 years $1,010,942.00 Intermittent ca
Slide 11: Growth Models
GROWTH MODELS For personal use only CAGR and 5 Year Projected Revenue 30 25 20 $M AUD 15 10 5 0 2017 2018 2019 2020 2021 2022 20% CAGR 32% CAGR 50% CAGR These are simple mathematical models and do not in any way represent forecasts
Slide 12: Relative Performance
R E L AT I V E P E R F O R M A N C E For personal use only ASX Indices 5 Year Compound PA Growth Rate (CAGR) 35 32 30 25 20 18 % 15 13 10 8 7 5 3 0.6 0
Slide 13: Our Acquisitions
OUR ACQUISITIONS For personal use only INVESTED IN NEW TECHNOLOGY Uscom has invested in technology with We have integrated the companies, 2018 will see the launch of 7 new two corporate acquisitions: central redesigned, optimised, and rebranded products to market, and new revenue. blood pressure, an
Slide 14: USCOM 1A, BP+ and SpiroSonic devices
The USCOM 1A is a non-invasive advanced SpiroSonic digital ultrasonic spirometers For personal use only hemodynamic monitor that measures are high fidelity, digital, pulmonary function cardiovascular function using Doppler testing devices based on multi-path ultrasound to detect abnormalities and ul
Slide 15: Our Benefits: Meeting Global Clinical Needs
OUR BENEFITS For personal use only TOP 10 CAUSES OF DEATH GLOBALLY – 2015 (WHO) Ischaemic heart disease MEETING GLOBAL CLINICAL NEEDS Stroke Lower repiratory infection Uscom devices address conditions responsible COPD for 75% of all deaths worldwide (WHO criteria). Tracheal, bronchus, lung cancers H
Slide 16: Regulatory
R E G U L AT O R Y For personal use only Regulatory approval is required for device sales into China (CFDA), Europe (CE), FDA (USA) and Australia (TGA). Uscom has a number of pending approvals into various jurisdictions over the next 12 months which will allow sales into new markets. USCOM 1A: BP+:
Slide 17: Our World
For personal use only OUR WORLD
Slide 18: Milestones
For personal use only MILESTONES FY17 Uscom made 23 price sensitive ASX announcements for the 2017 financial year.
Slide 19: Our Science
OUR SCIENCE For personal use only Patents and publications prove the value of Uscom technology to investors and the community. 30 Patents Patents provide the legal protection for the value of our IP, and Uscom has strong property protection of all its product suites. To defend future revenue streams
Slide 20: Product Launch
For personal use only PRODUCT LAUNCH
Slide 21: Mount Everest: It's a Big Deal
MOUNT EVEREST For personal use only IT’S A BIG DEAL • The BP+ is great science, and is: • On board the International Space Station • Used by UK servicemen and women to study hypertension on Mount Everest • In drug evaluation trials with big pharma • The emerging BP monitor of choice • Hypertension o
Slide 22: Lung Function
LUNG FUNCTION For personal use only F O R E V E RY B R E AT H Y O U TA K E Lung disease (asthma and COPD) occurs in approximately 20% of the population and is increasing SpiroSonic devices improve the diagnosis and treatment of lung disease Device redesign and rebranding complete New distribution in
Slide 23: Spirometry Software
For personal use only SPIROMETRY SOFTWARE DEVICES DEVICES A P P L I C AT I O N
Slide 24: Growth Strategy
G R O W T H S T R AT E G Y For personal use only Global CV and Pulmonary Devices Distribution and manufacturing Saving Lives – Uscom products Growth in revenue and scale • World leading devices • Global regulatory • Adoption • Grow revenue to $20M • New products in pipeline • China+ market expansion
Slide 25: Growth China
GROWTH CHINA For personal use only China USA 20 CHINA IS A MAJOR 18 S T R AT E G I C M A R K E T 1.4B population in 31 provinces 12 12 % 20% PA China health growth UCM CEO on NSW Government China Advisory 10 year history + China Government partners 5.8 5.5 CFDA BP+ and SpiroSonic initiated China rev
Slide 26: Growth Sales
GROWTH SALES Damien Linnett For personal use only Global Sales Manager GROWTH IN DISTRIBUTION AGREEMENTS Appointed 2017 Bea Onal 25 Marketing Coordinator Appointed 2017 16 12 11 Denise Pater 11 Global Distribution 50 Manager 41 43 36 6 23 12 Bev Jacobson 2013 2014 2015 2016 2017 2018* Clinical Relat
Slide 27: Investment
INVESTMENT For personal use only Uscom is a high growth, de-risked medical device and technology company. While this is a simple overview it demonstrates a commitment to continued growth and delivery on operational fundamentals. High value, de-risked investment ✓ Diversified, validated and lifesavin
Slide 28: Risks
RISKS For personal use only In a complex world unpredictable events can intervene in plans and strategies, and this also applies to Uscom, with a list of potential risks for the business going forward. While potential risks exist, management are always watchful and plan to respond rapidly and effect
Slide 29: Why Now
For personal use only WHY NOW After 5 years growth and investment Uscom is preparing for new revenue as we deliver 7 new products to global markets to supplement our already strong growth New products – 1 to 8 (+700%) More revenue – $3.5M to $10M, 20M, 50M New distribution – 53 to 75 (+32%) Incremen
Slide 30: Future Ambition
FUTURE AMBITION For personal use only HEALTHCARE REVENUE 2016 27.05 Multiple premium products with pipeline Proven growth trends Experienced management 18.29 Multiple markets and jurisdictions 16.67 15.77 17 China connections $B USD Patent protected IP 11.17 De-risked bio-tech 10.11 11 9.66 Small ca
Slide 31: Capital Growth
To build devices to meet current and impending volume sales orders For personal use only Complete regulatory processes in multiple jurisdictions Increase technical, marketing and sales staff to support expanding international operations Grow China market with new digital strategy, clinical support a
Slide 32: For personal use only
For personal use only "Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”
Slide 33: Competition: USCOM 1A
For personal use only NO Reliability and Replicability COMPETITION SV Beat to Beat Non-invasive 0 out of 10 of the market leaders can compete with the USCOM 1A The USCOM 1A’s superior Doppler technology is manufactured by Cost Effective Uscom, Australia. Portable Simple USCOM 1A - The Future of Hemo
Slide 34: USCOM 1A Competitors
USCOM 1A COMPETITORS For personal use only System Manufacturer Technology Rel+Rep Non-invasive Simple Cost Portable SV beat to beat Training USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ ✓ CardioQ Deltex Doppler ✓ ✗ ✓ ✗ ✓ ✗ ✗ Echo Many Ultrasound ✓ ✓ ✗ ✗ ✓ ✗ ✗ ICON / Aesculon Osypka Bio Impedance ✗ ✓ ✓ ✗ ✓ ✗ ✓
Slide 35: Competition: BP+
For personal use only Australian Made NO USD 2,950 45 Seconds COMPETITION Central blood pressure is the new gold standard measure for the Monitor ± Reporter detection and management of cardiovascular diseases. The BP+ and BP+ Reporter is the ideal cardiovascular research CE, FDA, TGA, CFDA * combina
Slide 36: BP+ Competitors
BP+ COMPETITORS For personal use only Uscom BP+ TensioMed BPLab IEM Alam Medical SunTech AtCor WelchAllyn Australia Hungary Russia Germany France USA Australia USA USD 2,950 USD 6,000 USD 7,000 USD 7,000 USD 3,200 USD 14,000 USD 3,200 A few sec + 45 seconds 2 min 2 min 2 min 1 min prep Stand-alone ±
Slide 37: Competition: SpiroSonic
For personal use only Australian made NO USD 1,890 Dual path ultrasound COMPETITION The SpiroSonic Ultrasonic spirometer uses high fidelity multi-path Accurate/auto calibration ultrasound for pulmonary function testing. Digital/Bluetooth/rechargeable FreeFlo sensor/Reporter/SpO2 Hygeinic SpiroSonic
Slide 38: SpiroSonic Competitors
SPIROSONIC COMPETITORS For personal use only Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland Dataspir SpiroSonic SpiroPerfect Spirovit SP-1 Pneumotrac Spirodoc Microloop EasyOne PLus Touch USD 1,890 USD 2,100 USD
Slide 39: Looking Forward
For personal use only LOOKING FORWARD FY18 is planned to be another year of growth.
Slide 40: Uscom News and Media
For personal use only USCOM USCOM NEWS “Companies like…Uscom are selling MEDIA Great opportunity to join The Premier of product world-wide and earning highly NSW, The Hon Gladys Berejiklian, the NSW significant export income and all are on the Minister for Health and Medical Research, verge of movin
Slide 41: Founder-Run
FOUNDER-RUN For personal use only “Research suggests that founder-run businesses outperformed the broader market. This seems intuitive, with firms like Amazon, Facebook, and Google being among the strongest performers in the world in recent years. Closer to home, Seek, Harvey Norman, Flight Centre,
Slide 42: Small Caps
SMALL CAPS For personal use only “The case for small caps to structurally outperform is stronger than ever. Reasons for this include: - The high level of inside ownership & alignment with investors - The leverage smalls have to M&A - Smalls are typically less researched than large caps which give in
Slide 43: For personal use only
For personal use only "Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”